Table 3. Ongoing trials for ovarian, fallopian and peritoneal cancers.
| Trial phase | Cancer type | Treatment arm | Control arm | Sponsor/country | Primary outcome | ECD |
|---|---|---|---|---|---|---|
| III | Ovarian | CyRS + HIPEC | CyRS | The Netherlands Cancer Institute, Netherland | RFS | 2015 |
| II | Ovarian, fallopian, and peritoneal | CyRS + HIPEC + AC | CyRS + AC | Mercy Medical Center, USA | Post-operative complication rates | 2016 |
| III | Ovarian* | Surgery + HIPEC | Surgery | UNICANCER, France | OS | 2018 |
| III | Ovarian* | Surgery + HIPEC | Surgery | Catholic University of the Sacred Heart, Italy | PFS | 2018 |
| III | Ovarian | CyRS + HIPEC | CyRS | A.O. Ospedale Papa Giovanni XXIII, Italy | DFS | 2018 |
*, recurrent ovarian cancer. No peritoneal carcinomatosis. ECD, estimated completion date; CyRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; RFS, recurrence free survival; AC, adjuvant chemotherapy; OS, overall survival; PFS, progression free survival; DFS, disease free survival.